Session » Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment:Treatment of PsA and SpA

Date: Monday, November 9, 2015

Time: 4:30PM-6:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 2144

Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis

Abstract Number: 2145

Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

Abstract Number: 2146

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing

Abstract Number: 2147

The Effect of Sulfasalazine and Methotrexate on the Immunogenicity of Infliximab and Adalimumab in Patients with Spondyloarthritis

Abstract Number: 2148

Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

Abstract Number: 2149

Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial

« View all sessions from this meeting